Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus
Abstract
In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. To update the consensus with new evidence.
A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previosly developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus.
A total of 70 studies were included (IBS, 34; diarrhoea ssociated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo.
Consensus statements with 100% agreement and "high" evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotic or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and "moderate" evidentce indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency.
This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publication did not report benefits of probiotic, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety.
This study will help clinicians recommend/prescribe probiotics for specific symptoms.